54.66 0.00 (0.00%)
After hours: 4:21PM EDT
|Bid||54.34 x 800|
|Ask||54.66 x 800|
|Day's Range||53.86 - 55.11|
|52 Week Range||53.25 - 71.04|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||11.96|
|Earnings Date||Jul 31, 2019|
|Forward Dividend & Yield||1.64 (3.03%)|
|1y Target Est||67.67|
Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of Molson Coors Brewing Company (“Molson Coors” or “the Company”) (NYSE: TAP). Shareholders of Molson Coors are advised to contact either John Kehoe, Esq., (215) 792-6676, Ext. 801, email@example.com or Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, firstname.lastname@example.org, email@example.com.
Molson Coors Brewing Co NYSE:TAPView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for TAP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding TAP are favorable, with net inflows of $8.77 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. TAP credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Aurora Cannabis (NYSE:ACG) isn't consistently profitable and has failed to meet Wall Street analysts' earnings estimates in three out of the past four quarters. Like other pot shares, ACG stock is on a tear, up more than 50% since the start of the year as investors bet that better times lie ahead.Source: Shutterstock However, expectations for Aurora stock don't appear to be justified by the fundamentals. The company's penchant for dilutive acquisitions is particularly troubling. Massive DilutionAs of the latest quarter, ACB had had more than 1 billion shares outstanding, more than twice the 478 million shares it had a year earlier. Rival Canopy Growth's (NYSE:CGC) share count is about 238 million. Fortune 500 stalwarts such as CBS (NYSE:CBS) (351.9 million), Southwest Airlines (NYSE:LUV) (543.7 million) and McDonald's (NYSE:MCD) (763.6 million), each have fewer shares outstanding than ACB.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Quality Cheap Stocks to Buy With $10 Let's not forget the options to purchase 19.96 million ACB shares awarded in March to billionaire Nelson Peltz when Aurora named him as a strategic advisor. Though Peltz certainly has the connections to make things happen for ACB, that award is still massive since the company's current top shareholder Vanguard "only" had 20.3 million shares, as of the end of 2018. Profitability StrugglesMeanwhile, ACB is struggling to achieve consistent profitability. Wall Street analysts are expecting the red ink to continue through at least 2020. They have an average price target on the stock of $14.27, a potential upside of 40% for reasons that elude me.A glut in the Canadian pot market will keep prices depressed for the next two to three years just as ACB ramps up production. While I realize that ACB aims to push down prices, it seems that the plan may work too well.Demand also hasn't been robust. According to Health Canada, total sales of dried cannabis grew 7% to 16,488 kilograms between January 1 and March 31 compared with October 16 to December 31, 2018. The total inventory of weed was 30,802 kilograms, as of the end of March, nearly twice the 18,940 kilograms at the end of December 2018. Negative View On BeveragesSpeaking during the company's recent earnings conference call, chief executive Terry Booth surprised investors with his negative comments regarding the demand for cannabidiol (CBD)-infused beverages given the reports that his company held talks with Coca-Cola (NYSE:KO) about a partnership. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 Other companies including Canopy, are more optimistic about the potential for CBD, which lacks the THC compound that makes users high, in beverages. Constellation Brands (NYSE:STZ) invested $4 billion in CGC last year. Anheuser-Busch InBev (NYSE:BUD) teamed up with Canadian pot producer Tilray (NASDAQ: TLRY) on a $100 million initiative to research uses of CBD in non-alcoholic beverages. Heineken's Lagunitas brewery released a non-alcoholic THC-infused beer called Hi-Fi Hops last year. Molson Coors (NYSE:TAP) joined forces with Quebec-based cannabis company HEXO to develop non-alcoholic beverages. Bottom Line on ACB StockThough I had some concerns about Canopy Growth, I like those shares more than ACB stock. Canopy's partnership with STZ gives it financial flexibility that Aurora Cannabis lacks. If you want to buy stock in the highly risky legal pot sector, there are better choices than ACB.-Jonathan Berr doesn't own shares in any of the stocks discussed in this post. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 7 Best Tech Stocks to Buy for the Second Half of 2019 * 7 Top-Rated Biotech Stocks to Invest In Today * 4 Semiconductor Stocks to Sell Compare Brokers The post Amid A Pot Stock Boom, I Have Misgivings About Aurora Cannabis Stock appeared first on InvestorPlace.
(Bloomberg) -- Molson Coors Brewing Co.’s cannabis joint venture plans to start selling multiple types of pot beverages on Canadian shelves the first day they can legally be sold, though they won’t contain alcohol.The maker of Coors Light has partnered with Gatineau, Quebec-based Hexo Corp. to make a variety of non-alcoholic, cannabis-infused drinks for the Canadian market. The joint venture, called Truss, will have “lots of different beverages” for sale on Dec. 16, when the beverages become legal in Canada, said Jay McMillan, Hexo’s vice president of strategic development.“We’ll have a very large supply so we’ll be in a good position to be able to meet the demand of the marketplace and at the same time also ensure that we’re meeting the variety that the marketplace wants,” McMillan said in an interview on the sidelines of the World Cannabis Congress in Saint John, New Brunswick.Guessing GamePot-infused drinks are sold in U.S. states though the regulations remain fuzzy. Makers of cannabis drinks have to play a bit of a guessing game about consumer tastes, as those currently on the market in the U.S. states often take a long time for the high to kick in, and can taste like “bong water,” McMillan said.Truss plans to offer everything from water to a “beer-like product” and maybe even hot beverages. It has flexible production lines so it can pivot if one type of beverage isn’t selling, he said.It’s also looking at selling CBD-infused beverages in the U.S., which legalized the non-intoxicating substance late last year, with the goal of having products in eight states by 2020.Canada will add edibles, beverages, vape pens and topicals to its list of legal cannabis products this fall, but they won’t be available on shelves until Dec. 16 at the earliest. Its regulations for the new formats include the stipulation that alcohol-related terms like “beer” and “wine” can’t be used to market pot drinks.“You’re going to have to call it a cannabis-infused yeast extract,” Darrell Dexter, executive director of the Cannabis Beverage Producers Alliance and former premier of Nova Scotia, joked in a panel discussion.To contact the reporter on this story: Kristine Owram in Toronto at email@example.comTo contact the editors responsible for this story: Brad Olesen at firstname.lastname@example.org, ;David Scanlan at email@example.com, Jacqueline ThorpeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Boston Beer (SAM) gains from momentum in shipment volume and depletion, driven by its three-point growth plan. This places it ahead of peers in an otherwise struggling alcohol industry.
With many cannabis stocks at sky-high valuations, there's little room for making mistakes. Just look at Hexo (NYSEAmerican:HEXO). On news of its latest earnings report, the stock price dropped 8.53%. Note that the HEXO stock price is about 50% off its 52-week high.Source: Shutterstock So let's drill-down on the quarter. For the bottom line, the company actually beat expectations. HEXO reported a loss of 7.75 million CAD ($5.77 million) , or 4 cents a share, while the consensus was for a loss of 5 cents a share.But the top-line was another story. Revenue came in at 13.02 million CAD yet the Street was looking for a more robust 14.8 million CAD. What's more, there was an 8.6% quarter-over-quarter drop in sales.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNow predicting quarterly numbers has not been easy as Canada is still in the early phases of legalization for recreational purposes. There are also ongoing shortages, supply complications and regulatory issues to deal with. * 7 Stocks to Buy for the Coming Recession But then again, investors are certainly baking in lots of growth. So it should be no surprise that HEXO stock took at hit.Here are some other worrisome metrics for the quarter: * The average price of adult-use dried grams dropped from $5.83 CAD in January to $5.29 CAD in April. * The average gross selling price per gram was also soft, going from $9.15 CAD to $9.11 CAD.But of course, there was also some good news in the report. The company announced it received a medical cannabis installation license from the Greek government for "cultivation, processing and manufacturing facilities."To this end, Hexo plans to begin construction of a 323,000 square-foot facility in the country by the fourth quarter of this year. No doubt, this should ultimately be a nice catalyst for long-term growth.In the meantime, Hexo has other promising initiatives. For example, the company has entered a partnership with Molson Coors (NYSE:TAP) to develop cannabis-infused beverages. There are also aggressive plans to benefit from the cannabidiol (CBD) market (this involves the use of compounds in the cannabis sativa plant that do not produce a high).With the passage of the U.S. farm bill last year, the category is likely to see a spike in growth in the coming years. According to research from the Brightfield Group, the market in the U.S. could hit $22 billion by 2022. Bottom Line on Hexo StockAccording to InvestorPlace's James Brumley, Hexo stock has been mostly overlooked -- say compared to names like Canopy Growth (NYSE:CGC), Tilray (NASDAQ:TLRY), Aurora Cannabis (NYSE:ACB) and Cronos Group (NASDAQ:CRON). I agree. * 7 High-Quality Cheap Stocks to Buy With $10 I also think this presents an opportunity for investors. Consider that Bank of America (NYSE:BAC) analyst Christopher Carey holds that Hexo stock has the most attractive valuation within his coverage universe. The price target is actually $10, which assumes a whopping 78% upside from current levels!Hexo's management is also not backing off its revenue estimates. They not only call for a doubling in the current quarter but $400 million CAD for fiscal year 2020, which does not include the impact from the Molson Coors's partnership.Now when it comes to cannabis stocks, there should always be caution. Again, the industry is in the early stages and there will likely be continued volatility. Let's face it, the competitive environment is getting more intense and the legal environment is far from certain.So yes, investors should be diligent with their money. But as for Hexo stock, there are certainly many positives, in terms of the global expansion, CBD opportunity and the growth in Canada.Tom Taulli is the author of the upcoming book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post Hexo Stock Has An Earnings Buzz Kill That Simply Isn't Deserved appeared first on InvestorPlace.
Disappointed with its latest quarterly results? The cannabis producer's CEO identified plenty of good news that should be on the way.
On Monday, Credit Suisse initiated Molson Coors Brewing Co. Credit Suisse proposed two scenarios, one of which has the stock rising to $71, and another which projects the shares falling to $43. Molson Coors has been in a bear channel (blue lines) for about three years, consisting of numerous lower highs and lower lows.
went flat Monday, falling 3.9% to $54.74 after Credit Suisse initiated coverage on the stock with an "underperform" rating and a $50 price target. "We believe the company faces significant hurdles in overcoming its portfolio exposure, and fear the time for bold decisions has passed," Credit Suisse said in a note to investors. Last month, Denver-based Molson Coors reported first quarter top- and bottom-line results that were below expectations.
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll show how you can use...
Investing.com - Shares of Molson Coors slumped in midday trading after a negative sell-side research note said there is no clear path for stabilization of the stock.
Molson Coors (TAP) witnesses soft volume in the United States and higher input costs resulting from tough industry conditions. But the company's premiumization and cost-saving efforts hold potential.
The Ontario government on Thursday passed legislation to end a contract with a beer retailer in Canada's most populous province calling it a monopoly, but business lobby groups say the abrupt cancellation discourages investment. Ontario's Progressive Conservative government's surprise proposal last month adds to its list of controversial decisions since coming to power last year, including spending cuts to healthcare and education. The new government is trying to rein in borrowing, which at C$346 billion ($259 billion) in net debt makes it the world's biggest issuer of sub-sovereign debt.
The chairman of Molson Coors Brewing Co. and a bottler for PepsiCo Inc. are urging the U.S. government to investigate the process used to set benchmark aluminum premiums, which have doubled from 2017 levels in the wake of U.S. import tariffs. The premium, which is meant to reflect transportation and handling costs along with the amount of supply available, is determined by London-based S&P Global Platts using its own market surveys. Beverage makers say that the process leaves itself open to manipulation, and want regulatory oversight of how it’s conducted.
You know you're writing too much about marijuana when a search for sector players like Hexo (NYSEAmerican:HEXO) brings up your own articles. And you really know you're going overboard when other analysts cite your work as expert opinion. But this "anything goes" dynamic really points to the broader opportunity in HEXO stock.Source: Shutterstock If I wrote about an established blue-chip name like Altria (NYSE:MO), I could probably search for days before my last article on the topic comes up. Everyone talks about Altria. Adding one more opinion on the subject is like relieving yourself in the Pacific Ocean. It matters, but only in the technical sense.On the other hand, discussing HEXO is like relieving yourself in the jacuzzi. It matters, especially if the jacuzzi water didn't originally have a yellowish tint.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Bank Stocks to Leave in the Vault What's the point about my biological analogies, you ask? Small actions can have a big impact on young markets. That sentiment applies to both directions, as the HEXO stock price recently demonstrated.On a year-to-date basis, shares of the cannabis firm are still at astonishingly elevated levels. However, since the April 29 close, Hexo stock has dropped 24% in the markets.Part of the reason why the equity collapsed involves the same motivation for why other marijuana stocks have gone volatile: good ol' fashioned profit taking. With Hexo stock doubling a little over a month ago, early investors bailed out.Secondly, as InvestorPlace contributor Ian Bezek pointed out, HEXO and other cannabis players have a credibility issue. You can't have a market capitalization in the billions and revenue in the millions indefinitely.But once the profit taking in Hexo stock fades, I'd consider going long for one reason: cannabidiol. Underappreciated OpportunityWe've passed the infancy stage of the cannabis revolution, which is participation. Of coure, this low-hanging fruit didn't last because growing marijuana isn't rocket science. Companies now are differentiating themselves through marijuana specialties, such as mass production or cultivating medically effective strains.How does HEXO distinguish itself from the pack? The answer is cannabidiol, or CBD.This isn't a new argument. In fact, it's quite an old one. As our own James Brumley noted early this year, CBD-infused beverages represent a crowded market. It's also a very modestly sized one in terms of revenue. Thus, critics have argued that this trend is a fad.On the surface, this circumstance bodes poorly for the HEXO stock price. The underlying company inked a promising venture with Molson Coors (NYSE:TAP) to produce CBD-infused beverages. But that potential dies if this niche fails to take off.Admittedly, early signs don't look encouraging. However, this is still a very young market where a series of small actions can spark something massive.I'm especially intrigued with CBD's medicinal potential. According to Harvard Health Publishing contributing editor Peter Grinspoon, some evidence exists for the cannabis plant's therapeutic claims. Dr. Grinspoon even cites research on marijuana's impact on traumatic brain injuries. * 7 Stocks to Buy for Monster Growth The obvious caveat is that more evidence is necessary to establish CBD as a genuine therapeutic platform. Still, that's what makes CBD, and indirectly Hexo stock, an exciting proposition. We don't yet fully understand marijuana because mainstream research on the plant is still relatively scarce. But the fact that at least some positive data exists is undeniable.That's also why I don't think CBD-infused beverages is a fad. This isn't a flavor of the week. Instead, the mainstreaming of CBD could eventually catalyze a paradigm shift in cannabis perceptions. Patience Could Go a Long Way with Hexo StockWhile Dr. Grinspoon's article is a recommended read, I especially encourage you to read the comments section.One caught my eye. A reader claimed that her mother suffered from severe pain, requiring opioids to cope. But with CBD and other cannabis-related medicines, she is able to enjoy a better quality of life.Rather than blast someone for using unproven alternative therapies, Dr. Grinspoon instead encouraged the weening off opioids. In my opinion, that's very telling coming from a medical doctor deeply embedded in the mainstream health care system.If you ask me, it appears medical professionals prefer natural CBD products over exotic pharmaceutical concoctions.But this is not a license to jump aboard Hexo without fully appreciating the risks. The HEXO stock price can just as quickly rise or erode. Like I said, it's a young market: an unwelcome stream can put an immediate damper on your relaxing jacuzzi.But if you drill down into the science and data, it's more likely that any surprises will be positive ones. Therefore, I'm interested in taking any significant dips in HEXO as longer-term buying opportunities.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Impacted by the Mexican Tariffs * 6 Big Dividend Stocks to Buy as Yields Plunge * The 10 Biggest Announcements From Apple WWDC 2019 Compare Brokers The post Underappreciated CBD Market Is The Key For HEXO Stock appeared first on InvestorPlace.
For generations, Czechs have consumed world-beating volumes of beer in the smoky, wood-panelled rooms of their local pubs, all but indistinguishable from each other bar the brand of lager flowing from the taps. Czechs are increasingly shunning fusty old watering holes and draft beer sales are sliding, so the world-famous brewers of pilsner are looking to inject some pizzazz into the traditional pub and attract younger patrons looking for a hip, modern feel. People like Marcel are the kinds of drinkers with disposable income that breweries such as Plzensky Prazdroj, the maker of Pilsner Urquell, are seeking to lure back with new concept bars designed to recharge the traditional Czech pub.
Monday blues is an understatement for New Age Beverages (NASDAQ:NBEV). The company announced that it would acquire food-and-beverage outfit Brands Within Reach, owner of Nestea, Evian and other labels. But with no details on the purchasing structure or even the ultimate price, the markets quickly upended NBEV stock.It's just as possible, however, that the setback was going to take shape anyway. In this scenario, traders were simply waiting for the right excuse to make it happen.InvestorPlace - Stock Market News, Stock Advice & Trading TipsRegardless of the true reason behind Monday's selloff, the move has very likely done some technical damage to NBEV stock. Eventually, this impairment will lead to more downside. Perhaps worse, the cannabis backstory that kept so many overvalued names moving higher appears to have run its full course.Now, this narrative won't be useful again as a bullish talking point. Traders Never BelievedThere's no denying it: New Age Beverages stock rode the cannabis craze. In September, management announced that it would launch a CBD lineup of beverages in the foreseeable future. * 7 Bank Stocks to Leave in the Vault This decision followed a well-worn pathway. For instance, the planned joint venture between Constellation Brands (NYSE:STZ) and Canopy Growth (NYSE:CGC), and the partnership between Hexo (NYSEAMERICAN:HEXO) and Molson Coors (NYSE:TAP) forged similar synergies.However, New Age Beverages arguably beat them all to the punch. The unveiling of its Marley (as in Bob Marley) brand during the fall of last year was a massive catalyst. It pushed NBEV stock from $1.53 to a peak of $9.99 in the span of just five trading days.A huge swath of traders, however, never really believed that surge was meant to last.As of the latest look, more than 30% of outstanding shares of NBEV stock (and more than 32% of the float) were held as short positions. These are risky bets that the equity will move lower rather than higher. For perspective, a typical short ratio for a less-hyped ticker might be on the order of (very) low single digits. Even riskier names like Hexo and Canopy Growth are only sporting short interest of 5% and 8%, respectively, right now.Such a degree of doubt can have one of two polar-opposite outcomes. On one hand, an "upside panic" could force short sellers to buy NBEV stock to close out their bearish position. On the other, all those short sellers could be right, and shares crumble.Given the shape of New Age Beverages stock for the past several weeks followed with Monday's move lower, it's difficult to say the bears and doubters didn't make the right call. But their party is far from over considering the technical damage done on Monday. Charting New Age Beverages StockMany securities have survived worse than Monday's 6% setback. But in this case, even the low-volume move lower portends more problems. Click to Enlarge Chief among the red flags is the way the tumble carried NBEV stock below the lower edge of a converging wedge pattern that had been forming since September's peak. A close second concern is the fact that the selloff also dragged New Age Beverages stock below a recently developed technical floor around $5.04 (yellow) as well as under its 200-day moving average line (white).Some bulls are already pushing back, but not enough of them. As long as they're unable to push shares back above $5.04, the bears remain in control. They're also well-positioned to take another, more damaging swipe.As for the profitable short sellers that haven't bailed out, they're not likely to do so now. The risky phase of their trade is now in the rear-view mirror. Their next task is pinpointing where the next most likely bottom is now that the previous most-likely floor has been broken as support. Looking Ahead for NBEV StockEventually, all of those short sellers will have to close out their positions by buying NBEV stock back. But anyone anticipating a short-squeeze rally taking shape in the near future is betting on the less likely outcome.With a lack of volume following the stumble, a dead-cat bounce doesn't appear to be in the cards. And with the purchase of an entity that's outside of the cannabis realm -- suggesting there are fewer cannabis-related acquisition options -- the bullish case for NBEV stock further deteriorates. That's because marijuana was the only thing really propping this name up. Even then though, the marijuana narratives weren't doing a great job.Monday's action is likely to be the nail in that coffin, keeping shares subdued for the foreseeable future.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Heavily Shorted Stocks to Sell -- Because the Bears Are Right * 7 Bank Stocks to Leave in the Vault * 7 Stocks for You to Profit From (Legal) Insider Trading Compare Brokers The post Even Under $5, New Age Beverages Stock May Not Be Done Falling appeared first on InvestorPlace.
Molson Coors (TAP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
[Editor's note: This story was previously published in March 2019. It has since been updated and republished.]Traffic stats don't lie: among investment categories, few have the draw of legal marijuana. And within this broad segment, companies specializing in cannabidiol, or CBD, have generated significant buzz. But what exactly is this three-letter acronym, and how can CBD stocks boost your returns?Let's start with basic definitions. Cannabidiol represents one of several cannabinoids, or chemical compounds found in the cannabis sativa plant. But unlike the most famous cannabinoid tetrahydrocannabinol (THC), CBD does not trigger any psychoactive effect. In other words, users can enjoy this compound's benefits without getting high.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis opens up profound opportunities for marijuana stocks that have exposure to CBD. First, since this compound inherently lends itself to medicinal use, it tends to be treated favorably by legislation. Most states allow CBD use for therapeutic purposes. Given political and public sentiment, it's not inconceivable that all states will eventually green-light cannabidiol.Second, CBD has the potential to help solve a huge societal problem. Turn on the news, and you'll eventually find stories about the raging opioid crisis. What is less reported is that pharmaceutical companies contributed to the problem with highly addictive painkillers. Since CBD is not physically addictive, it could be a viable replacement for many addictive opioids.Finally, the U.S. may be the leader of the free world, but it stymies itself with antiquated laws. Our neighbors to the north became the first G7 nation to legalize recreational weed, while we still classify cannabis as a Schedule I narcotic. Still, our laws will eventually reach the 21st century. When they do, marijuana stocks of all stripes should realize their full potential. * 7 Stocks to Sell Amid an Escalating Trade War In the meantime, here are four CBD stocks to consider adding to your portfolio: Tilray (TLRY)Source: Shutterstock When it comes to medicinal marijuana, few cannabis stocks have generated as much positive traction as Tilray (NASDAQ:TLRY). Last fall, TLRY stock soared to the stratosphere as the underlying firm received approval from the Drug Enforcement Administration to import weed for medical research. While shares have since come down significantly from those highs, Tilray remains a powerful name among CBD stocks. Recently, management signaled that it will aggressively compete in the cannabidiol sector with its acquisition of Manitoba Harvest. Manitoba specializes in CBD-infused food and health products, providing Tilray a key advantage in the North American market.From a technical perspective, speculators may want to dive into currently discounted levels. After the crazy phase in marijuana stocks dried up, several names fell under the radar. One of those is TLRY stock, which has mostly moved sideways this year.But with CBD gaining momentum stateside, who knows how long this discount will last? Aurora Cannabis (ACB)Source: Shutterstock Much of the enthusiasm towards Edmonton-based CBD (and THC) firm Aurora Cannabis (NYSE:ACB) came off the back of an analyst upgrade. Cowen Equity Research initiated coverage of ACB stock, rating it as "outperform," and giving it a rich price-target premium.But it's also interesting to note why Cowen is so optimistic. Analysts there view favorable international opinion towards marijuana as being beneficial to ACB stock over the long term. It's not an unreasonable thesis. Among CBD stocks, Aurora has made a significant dent in the global medical-marijuana field. * 7 Stocks to Sell Amid an Escalating Trade War Plus, the company has a massive market down south. While we're fiercely divided politically, marijuana legalization is something Americans agree on more than most things. Hexo (HEXO)Source: Shutterstock Invariably, marijuana stocks are incredibly risky. While legalization initiatives have opened opportunities, this is a double-edged sword as competitors swarm into the arena. What you're left with are several companies like Hexo (AMEX:HEXO), which suffer from severely-challenged financials. But despite the risks, cannabis investors should strongly consider CBD stocks like HEXO. Since cannabidiol doesn't produce any psychoactive or addictive responses, it facilitates surprisingly broad synergies. A prime example is the budding relationship with marijuana firms and beverage-makers.Last summer, Hexo entered a joint venture with Molson Coors Brewing (NYSE:TAP) to produce CBD-infused drinks. Naturally, HEXO stock jumped off the news before giving up those gains late last year.However, shares are making a strong comeback this year, jumping to a 100% lead. While it's incredibly volatile, further positive developments could easily lift HEXO stock to its prior highs. BlissCo Cannabis (HSTRF)Source: Shutterstock I always warn folks that cannabis and CBD stocks are risky because that's God's honest truth. But BlissCo Cannabis (OTCMKTS:HSTRF) is an entirely different ballgame. HSTRF stock is so speculative that it makes other companies in this sector look stable. We can start with the fact that shares currently sell for 29 cents a pop. Unlike some of the established names, the historical trend for HSTRF stock is decidedly negative. Finally, I don't think I need to say this but BlissCo has severe fiscal challenges.So why am I mentioning this company? Simple…upside potential. Partnering with both medical professionals and alternative therapists, BlissCo is a known commodity in Canada's medicinal-cannabis industry. * 7 Stocks to Sell Amid an Escalating Trade War Year-to-date, shares are up nearly 39%. As BlissCo remains undervalued relative to its historical averages, there's probably substantial room for growth.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy for June * 7 Stocks to Buy From One of America's Best Pension Funds * 4 Consumer Staples Stocks for Both Income and Growth Compare Brokers The post 4 CBD Stocks to Buy for Mainstream Marijuana Profits appeared first on InvestorPlace.